Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.

Original publication

DOI

10.1016/j.amjcard.2004.01.073

Type

Journal article

Journal

Am J Cardiol

Publication Date

15/05/2004

Volume

93

Pages

1309 - 1312

Keywords

Adjuvants, Immunologic, Aged, Cardiotonic Agents, Fas Ligand Protein, Female, Heart Failure, Humans, Hydrazones, Infusions, Intravenous, Interleukin-6, Male, Membrane Glycoproteins, Pyridazines, Ventricular Function, Left